{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:16:35Z","timestamp":1758759395507,"version":"3.44.0"},"reference-count":24,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T00:00:00Z","timestamp":1752624000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pediatric Dermatology"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>To evaluate the risk of otitis media (OM) and related surgical procedures among population\u2010based, propensity score\u2010matched cohorts of patients with atopic dermatitis (AD) treated with dupilumab compared to those treated with pimecrolimus.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The TriNetX research network was used to conduct a retrospective cohort study estimating the risk of all OM, nonsuppurative OM, suppurative OM, and subsequent surgical intervention in patients with AD treated with dupilumab compared to those treated with pimecrolimus, including an age\u2010stratified analysis focused on pediatric patients. Cohorts were propensity score matched by age at index, current age, sex, race, other atopies, and exposure to tobacco smoke. 5\u2010year Cox proportional hazards models with 95% confidence intervals were analyzed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>This study demonstrates that compared to those treated with pimecrolimus, AD patients treated with dupilumab have a significantly decreased 5\u2010year risk of all OM (HR, 0.60; 95% CI, 0.54\u20130.67; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), nonsuppurative OM (HR, 0.60; 95% CI, 0.52\u20130.70; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), suppurative OM (HR, 0.61; 95% CI, 0.55\u20130.69; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), and related surgical procedures (HR, 0.73; 95% CI, 0.58\u20130.90; <jats:italic>p<\/jats:italic>\u2009=\u20090.004), with similar results found among those &lt;\u200918\u2009years old.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Overall, reduced risk of OM and related surgical procedures is observed in patients with AD treated with dupilumab compared to those treated with pimecrolimus.<\/jats:p><\/jats:sec>","DOI":"10.1111\/pde.16008","type":"journal-article","created":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T04:29:21Z","timestamp":1752726561000},"page":"966-970","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dupilumab Treatment for Atopic Dermatitis Is Associated With Decreased Risk of Otitis Media and Related Surgical Procedures: A Retrospective Cohort Study"],"prefix":"10.1111","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8011-8433","authenticated-orcid":false,"given":"Matthew H.","family":"Lanehart","sequence":"first","affiliation":[{"name":"Department of Dermatology West Virginia University  Morgantown West Virginia USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9029-6690","authenticated-orcid":false,"given":"Breanne","family":"Hayes","sequence":"additional","affiliation":[{"name":"Section of Allergy and Immunology, Department of Pediatrics West Virginia University  Morgantown West Virginia USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zachary","family":"Zinn","sequence":"additional","affiliation":[{"name":"Department of Dermatology West Virginia University  Morgantown West Virginia USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David P.","family":"Skoner","sequence":"additional","affiliation":[{"name":"Section of Allergy and Immunology, Department of Pediatrics West Virginia University  Morgantown West Virginia USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,7,16]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00405\u2010010\u20101297\u20109"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.3109\/00016488809125100"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2007.06.041"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/archotol.1988.01860220065025"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2002.125697"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.2310\/7070.2004.03073"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2004.07.061"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/archotol.1986.03780080040008"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.2500\/aap.2012.33.3529"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2024.12.014"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anl.2010.11.016"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365\u20102222.2005.02330.x"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11040926"},{"volume-title":"Dupixent (Dupilumab) [Package Insert]","year":"2024","author":"Regeneron Pharmaceuticals, Inc","key":"e_1_2_8_15_1"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.08.047"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.16265"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.09.052"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2023.03.007"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anl.2020.09.001"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40413\u2010017\u20100168\u2010x"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.28019"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2019.06.023"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2000024"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11882\u2010017\u20100693\u20102"}],"container-title":["Pediatric Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/pde.16008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T14:45:38Z","timestamp":1758725138000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/pde.16008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,16]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.1111\/pde.16008"],"URL":"https:\/\/doi.org\/10.1111\/pde.16008","archive":["Portico"],"relation":{},"ISSN":["0736-8046","1525-1470"],"issn-type":[{"type":"print","value":"0736-8046"},{"type":"electronic","value":"1525-1470"}],"subject":[],"published":{"date-parts":[[2025,7,16]]},"assertion":[{"value":"2025-01-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}